

1 **Effects of vitamin D supplementation and seasonality on circulating cytokines in**
2 **adolescents: analysis of data from a feasibility trial in Mongolia.**

3 Sergey Yegorov^{1*}, Sabri Bromage², Ninjin Boldbaatar³, Davaasambuu Ganmaa^{2,4,5}

4

5 ¹ Department of Science Education, Faculty of Education and Humanities, Suleyman
6 Demirel University, Almaty, Kazakhstan

7 ² Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA,
8 United States of America

9 ³ Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's
10 Hospital, Boston, MA

11 ⁴ Channing Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston,
12 MA, United States of America

13 ⁵ Health Sciences University of Mongolia, Ulaanbaatar, Mongolia

14

15

16 **Author emails:**

17 sergey.yegorov@sdu.edu.kz (SY), sbromage@mail.harvard.edu (SB),

18 nboldbaa@gmail.com (NB), gdavaasa@hsph.harvard.edu (GD).

19

20 ***Corresponding author**

21 sergey.yegorov@sdu.edu.kz (SY)

1 **ABSTRACT.**

2 Vitamin D deficiency is prevalent in human populations and has been linked to immune
3 dysfunction. Here we explored the effects of cholecalciferol supplementation on circulating
4 cytokines in severely vitamin D deficient (blood 25(OH)D₃ << 30 nmol/L) adolescents
5 aged 12-15 from Mongolia. The study included 28 children receiving 800 IU daily
6 cholecalciferol for 6 months spanning winter and spring, and 30 children receiving placebo
7 during the same period. The levels of 25(OH)D₃ were assessed at baseline, three and six
8 months. Twenty-one cytokines were measured in serum at baseline and at six months. The
9 median blood 25(OH)D₃ concentration at baseline was 13.7 nmol/L (IQR=10.0-21.7).
10 Supplementation tripled blood 25(OH)D₃ levels (p<0.001) and reversed the direction of
11 change for most cytokines (16/21, 86%). Supplementation was associated with elevated
12 interleukin (IL)-6 (p=0.043). The placebo group had reduced MIP-1 α (p=0.007) and IL-8
13 (p=0.034) at six months. These findings suggest that cholecalciferol supplementation and
14 seasonality have a measurable impact on circulating cytokines in adolescents, identifying
15 chemokines as potentially important biomarkers of vitamin D status in this population.

16

17 ***Keywords:** Vitamin D deficiency, cholecalciferol supplementation, cytokines, Mongolia,
18 adolescents

19 **ClinicalTrial.org ID:** NCT01244204

20

21 **INTRODUCTION.**

22 Accumulating evidence indicates that vitamin D has important non-skeletal functions,
23 particularly in the immune system (1-5). In particular, vitamin D deficiency has been

1 associated with increased risk for diseases tightly linked to immune function, such as
2 autoimmune conditions and respiratory tract infections (1, 4-6). Notably, a recent meta-
3 analysis found that vitamin D supplementation significantly reduced the risk of acute
4 respiratory infections most prominently in individuals with low blood 25(OH)D
5 concentrations (<25 nmol/L) (7), and in our earlier studies in Mongolian children, in whom
6 vitamin D deficiency (25(OH)D₃ <25 nmol/L or 10 ng/ml (8)) prevalence exceeds 80%, we
7 observed a significant reduction of acute respiratory tract infection associated with
8 cholecalciferol supplementation (9, 10). Similar observations were made regarding the
9 relationship of vitamin D and immunity to TB infection in other cohorts (2).

10 The *in vivo* effects of vitamin D on immunity are incompletely understood in the context
11 of different human populations and genetic backgrounds (3), although studies performed *in*
12 *vitro* and in animal models indicate that the nature of vitamin D effects on immunity is
13 context- and cell type-dependent. For example, vitamin D exerts stimulatory effects on
14 monocytes and macrophages inducing interleukin (IL)-1 production, while modulating
15 adaptive immune responses by increasing IL-10 production by dendritic and T cells (1, 5).

16 Given the protective effects of vitamin D against respiratory infections and the evidence
17 of the vitamin's immune roles *in vitro*, here we tested the hypothesis that six months of
18 cholecalciferol supplementation in vitamin D-deficient adolescents would result in a
19 significant change in the circulating mediators of antiviral and antibacterial immunity.

20

21 **METHODS.**

22 **Study setting and participant recruitment.**

23 This study is part of a feasibility pilot trial (completed in 2010) to assess the effects

1 of vitamin D supplementation on latent TB incidence in 120 Mongolian children
2 (ClinicalTrials.org ID: NCT01244204) (9). The screening and recruitment of participants
3 was described previously (9, 11). Briefly, children aged 12-15 years residing in
4 Ulaanbaatar, the capital of Mongolia, were recruited. The study intervention consisted of
5 800 IU vitamin D or placebo (Tishcon Corp., Salisbury, MD) daily for 6 months from
6 November 2009 to May 2010, during the coldest 6 months of the Mongolian year. For the
7 current study 58 paired serum samples (baseline and six months) were randomly selected
8 from the parent placebo (n=30/59) and supplemented (n=28/61) groups. This study was
9 designed to supply pilot data for future immune studies in the same cohort, therefore no
10 formal sample size calculations were performed and sample size was determined based on
11 the available study budget. All study procedures were approved by the institutional review
12 boards of the Mongolian Ministry of Health, National University of Mongolia and the
13 Harvard School of Public Health (Ref. #16571). Written consent to participate was
14 collected from both children and their parents.

15 **Sample collection and diagnostic testing.**

16 Blood (8.0 ml) was collected by venipuncture into red top tubes (Becton
17 Dickinson). Serum was isolated by centrifugation and stored at -80°C prior to shipping for
18 analysis to the United States. Measurement of 25(OH)D₃ was performed using Liaison
19 25(OH)D₃ Vitamin D total assay at 0, three and six months. The concentrations of 21
20 cytokines representing chemokines (macrophage inflammatory protein (MIP)-1 α , MIP-1 β ,
21 MIP-3 α , interleukin (IL)-8, fractalkine, interferon-inducible T-cell alpha chemoattractant
22 (ITAC), homeostatic (IL-2, IL-7, granulocyte-macrophage colony-stimulating factor (GM-
23 CSF), classic proinflammatory (IL-1 β , IL-6, tumour necrosis factor (TNF), Th17-type

1 proinflammatory (IL-17 α , IL-23), regulatory (IL-10, IL-21) as well as Type I (interferon
2 (IFN) γ , IL-12) and Type II cytokines (IL-13, IL-4, IL-5) (see **Supplementary Table 1** for
3 details) were measured at baseline and at 6 months using the Human High Sensitivity T
4 Cell Panel (HSTCMAG-28SK) on a MAGPIX instrument (EMD Millipore). All
5 experimental assays were performed by research personnel blinded to the supplementation
6 status of participants.

7 **Statistical analysis.**

8 Differences in demographic characteristics between the cholecalciferol supplemented and
9 placebo groups were assessed using Independent-Samples Mann-Whitney U and Chi-
10 Square Tests. Mean height-for-age and height-for-BMI z scores were calculated using
11 WHO Anthro software (12). Cytokine concentrations were Log₁₀-transformed prior to
12 analysis to facilitate visualization, while hypothesis testing was performed on the original
13 (not transformed) data. Serum 25(OH)D and cytokine concentrations across study visits
14 were compared using paired t-test, while differences between the placebo and
15 cholecalciferol supplemented groups at each time point were assessed by one sample t-test.
16 To compare the cumulative change in cytokine concentrations between the supplemented
17 and placebo groups, we first calculated the proportion of cytokines that were found on
18 average increased or decreased at follow-up for each participant group (solid dots for each
19 cytokine in **Figure 2**), and then performed a Chi-Square test of the null hypothesis that
20 there was no significant change in cumulative cytokine concentrations between the placebo
21 and cholecalciferol-supplemented children. All statistical analyses and graphing were
22 performed using IBM SPSS V.23 (NY, US) and GraphPad Prism V.6.0. (CA, US).

23

1 **RESULTS.**

2 **Participant demographics.**

3 Samples from a total of 58 children were analyzed. At baseline the median serum
4 25(OH)D₃ concentration was 13.7 nmol/L and basic socio-demographic characteristics
5 were not significantly different between the supplemented and placebo groups
6 (**Supplementary Table 2**).

7

8 **Changes in systemic 25(OH)D₃ concentrations.**

9 First, we examined blood 25(OH)D₃ levels at baseline (November) and three and six
10 months (February and May, respectively) (**Figure 1**). Children receiving placebo had
11 significantly reduced 25(OH)D₃ in February (mean= 10.6 nmol/L, mean fold change
12 (MFC)=1.4, p<0.001) and an increase of 25(OH)D₃ in May (mean= 23.2 nmol/L,
13 MFC=1.5, p<0.001) compared to November. On the other hand, children receiving
14 cholecalciferol exhibited an elevation of 25(OH)D₃ in February (mean= 44.3 nmol/L,
15 MFC=3.1, p<0.001) and this increase was sustained in May (mean= 49.0 nmol/L,
16 MFC=3.5, p<0.001) compared to November. Compared to the placebo group,
17 cholecalciferol supplemented participants had significantly higher blood 25(OH)D₃ levels
18 in both February (4.2-fold, p<0.001) and May (2.1-fold, p<0.001) (**Figure 1**).

19

20 **Changes in systemic cytokine concentrations.**

21 Due to missing data, paired cytokine analysis was performed for 49 (27 placebo and 22
22 supplemented) participants. First, we compared intra-participant changes in cytokine
23 concentrations between baseline and six months after study initiation (**Figure 2**). In the

1 supplemented group, 85.7% (18/21) and 14.3% (3/21) of measured cytokines exhibited a
2 positive and negative change, respectively, while in the placebo group the mean difference
3 in cytokine concentrations was negative for 76.2 % (16/21) and positive for 23.8% (5/21) of
4 the assessed cytokines. Thus, cholecalciferol supplementation had a significant effect on
5 the cumulative change in blood cytokine concentrations compared to placebo (Chi-square
6 statistic= 16.2, $p < 0.001$). The cholecalciferol supplemented group had elevated IL-6
7 (MFC=1.4, $p = 0.043$) (**Figure 2** and **Supplementary Figure 1**), while the levels of
8 chemokines MIP-1 α and IL-8 were significantly reduced in the placebo group (MFC= 2.38,
9 $p = 0.007$ and MFC=1.31, $p = 0.034$ for MIP-1 α and IL-8, respectively, **Figure 2** and
10 **Supplementary Figure 1**). The mean cytokine concentrations did not significantly differ
11 between the placebo and supplemented groups at baseline or at six months.

12

13 **DISCUSSION.**

14 In this study the supplemented group's 25(OH)D₃ concentrations increased gradually
15 reaching 49 nmol/L at six months, while the un-supplemented adolescents remained
16 severely deficient with blood 25(OH)D₃ levels remaining <25 nmol/L throughout the study,
17 linking the observed cytokine changes with the recent meta-analysis findings indicating that
18 25 nmol/L is a critical threshold of vitamin D deficiency associated with elevated risk for
19 acute respiratory infection (7). Interestingly, in May the placebo group had higher
20 25(OH)D₃ concentrations compared to November, although these levels were still under the
21 critical threshold of 25 nmol/L (**Figure 1**)

22 Compared to baseline, six months of cholecalciferol supplementation resulted in a
23 cumulative shift toward elevation for a majority (~86) of measured cytokines. This was in

1 stark contrast with the effect seen in the placebo group, where compared to baseline ~76%
2 of cytokines exhibited a cumulative shift toward reduction, suggesting that vitamin D
3 deficiency could contribute to a gradual change of immune variables over winter. Further,
4 the vitamin D-deficient children had significantly reduced MIP-1 α (CCL3) and IL-8
5 (CXCL8) concentrations at six months compared to baseline. This effect was not seen in
6 the supplemented participants, suggesting that vitamin D deficiency is implicated in the
7 reduction of these chemokines playing roles in leukocyte homing and activation and
8 mediating antibacterial and antiviral immune responses. Previously, vitamin D
9 supplementation in the context of chronic kidney disease was implicated in decreasing the
10 concentrations of another chemokine, monocyte chemoattractant protein-1, and our
11 findings provide further evidence for the role of vitamin D in chemokine homeostasis (13).

12 The increased IL-6 observed in the supplemented children is consistent with *in vitro*
13 studies showing that macrophages and monocytes up-regulate IL-6 expression upon
14 vitamin D stimulus (1) and IL-6 expression is up-regulated in the peripheral blood
15 mononuclear cells of vitamin D supplemented multiple sclerosis patients (14). At the same
16 time vitamin D supplementation was found to down-regulate IL-6 in some studies (15-18).
17 These seemingly contradictory findings regarding IL-6 and vitamin D could be attributed to
18 various confounders and differences among the studies, such as the duration and dosage of
19 vitamin D supplementation, the participants' genetic background, underlying clinical
20 conditions and extent of vitamin D insufficiency/deficiency at baseline.

21 Our findings are consistent with other studies reporting an increase of IL-10 in vitamin
22 D supplemented individuals (19-21), as we also observed a strong trend to elevated IL-10
23 in the supplemented children. Somewhat surprisingly, we saw no change in IFN- γ in our

1 study, the Type I cytokine that was significantly elevated in vitamin D-supplemented US
2 and Mexican adults (19, 20), which could reflect the diverse effects of vitamin D in
3 different age and/or ethnic groups.

4 Our findings should be interpreted in the light of limitations. First, the study was
5 designed as a pilot with a small sample size, which must have reduced the power to detect
6 small differences in cytokine concentrations. The small sample size also limited our choices
7 for data analysis, and we were unable to employ multivariable modeling in this study. Our
8 analysis was also limited by the cytokine panel size and time points included in the study.
9 Lastly, we tested the effects of a rather conservative vitamin D regimen and future studies
10 should assess the effects of different supplementation protocols on systemic immune
11 mediators.

12 In summary, this study for the first time assessed the immune effects of cholecalciferol
13 supplementation in adolescents from North/East Asia. Although it is challenging to
14 differentiate between the effects of vitamin D supplementation versus seasonality, six
15 months of cholecalciferol supplementation had a perceivable impact on systemic immune
16 mediators in this population. Future studies should explore in more detail the utility of the
17 identified cytokines as biomarkers of vitamin D-mediated immune function and the
18 associations of the identified immune pathways with clinical outcomes.

19

1 **DECLARATIONS.**

2 **Acknowledgements**

3 This study was supported by the NIH/NHLBI 1K99HL089710-01A1 grant to GD. We
4 acknowledge the support of Harvard Catalyst - Laboratory for Innovative Translational
5 Technologies (HC-LITT) at Harvard Institutes of Medicine with cytokine assays. We thank
6 all the participants and research teams involved in the study. We are especially grateful to
7 Yaruuna Enkhbold, Sonom Boldbataar, Jeremy Furtado, Allison Halleck, Gansuvd
8 Balgansuren, Purevdorj Olkhanuud and Winston Patrick Kuo for their technical advice and
9 expertise. We thank Dr. Adrian Martineau for the comments on the earlier draft of the
10 manuscript.

11

12 **Availability of data and materials**

13 All data generated or analyzed during this study are included in this published article.

14

15 **Authors' contributions**

16 Conceptualization, Sergey Yegorov and Davaasambuu Ganmaa; Data curation,
17 Davaasambuu Ganmaa; Formal analysis, Sergey Yegorov and Sabri Bromage; Funding
18 acquisition, Davaasambuu Ganmaa; Investigation, Sergey Yegorov, Sabri Bromage, Ninjin
19 Boldbaatar and Davaasambuu Ganmaa; Methodology, Ninjin Boldbaatar; Project
20 administration, Davaasambuu Ganmaa; Resources, Davaasambuu Ganmaa; Supervision,
21 Davaasambuu Ganmaa; Visualization, Sergey Yegorov; Writing – original draft, Sergey
22 Yegorov; Writing – review & editing, Sabri Bromage, Ninjin Boldbaatar and Davaasambuu

1 Ganmaa.

2 **Ethics approval and consent to participate.**

3 All study procedures were approved by Harvard School of Public Health IRB and
4 Mongolian Ministry of Health ERB. Written informed consent was obtained from all
5 children and their parents.

6 **Competing interests.**

7 The authors declare that they have no competing interests.

8 **Supplementary information**

9 Supplementary information for this article includes Supplementary Tables 1 and 2 and
10 Supplementary Figure 1.

11

12 **REFERENCES**

- 13 1. Mora JR, Iwata M, von Andrian UH. Vitamin effects on the immune system:
14 vitamins A and D take centre stage. *Nat Rev Immunol.* 2008;8(9):685-98.
- 15 2. Muscogiuri G. Vitamin D: past, present and future perspectives in the prevention of
16 chronic diseases. *Eur J Clin Nutr.* 2018;72(9):1221-5.
- 17 3. Mason RS, Sequeira VB, Gordon-Thomson C. Vitamin D: the light side of
18 sunshine. *Eur J Clin Nutr.* 2011;65(9):986-93.
- 19 4. Hewison M. Vitamin D and the immune system: new perspectives on an old theme.
20 *Endocrinol Metab Clin North Am.* 2010;39(2):365-79, table of contents.
- 21 5. Hewison M. Vitamin D and the intracrinology of innate immunity. *Mol Cell*
22 *Endocrinol.* 2010;321(2):103-11.

- 1 6. Gubatan J, Mitsuhashi S, Longhi MS, Zenlea T, Rosenberg L, Robson S, et al.
2 Higher serum vitamin D levels are associated with protective serum cytokine profiles in
3 patients with ulcerative colitis. *Cytokine*. 2018;103:38-45.
- 4 7. Martineau AR, Jolliffe DA, Hooper RL, Greenberg L, Aloia JF, Bergman P, et al.
5 Vitamin D supplementation to prevent acute respiratory tract infections: systematic review
6 and meta-analysis of individual participant data. *BMJ*. 2017;356:i6583.
- 7 8. Pearce SH, Cheetham TD. Diagnosis and management of vitamin D deficiency.
8 *BMJ*. 2010;340:b5664.
- 9 9. Ganmaa D, Giovannucci E, Bloom BR, Fawzi W, Burr W, Batbaatar D, et al.
10 Vitamin D, tuberculin skin test conversion, and latent tuberculosis in Mongolian school-age
11 children: a randomized, double-blind, placebo-controlled feasibility trial. *Am J Clin Nutr*.
12 2012;96(2):391-6.
- 13 10. Camargo CA, Jr., Ganmaa D, Frazier AL, Kirchberg FF, Stuart JJ, Kleinman K, et
14 al. Randomized trial of vitamin D supplementation and risk of acute respiratory infection in
15 Mongolia. *Pediatrics*. 2012;130(3):e561-7.
- 16 11. Ganmaa D, Stuart JJ, Sumberzul N, Ninjin B, Giovannucci E, Kleinman K, et al.
17 Vitamin D supplementation and growth in urban Mongol school children: Results from two
18 randomized clinical trials. *PLoS One*. 2017;12(5):e0175237.
- 19 12. de Onis M, Onyango AW, Borghi E, Siyam A, Nishida C, Siekmann J.
20 Development of a WHO growth reference for school-aged children and adolescents. *Bull*
21 *World Health Organ*. 2007;85(9):660-7.

- 1 13. Alvarez JA, Zughair SM, Law J, Hao L, Wasse H, Ziegler TR, et al. Effects of
2 high-dose cholecalciferol on serum markers of inflammation and immunity in patients with
3 early chronic kidney disease. *Eur J Clin Nutr.* 2013;67(3):264-9.
- 4 14. Naghavi Gargari B, Behmanesh M, Shirvani Farsani Z, Pahlevan Kakhki M, Azimi
5 AR. Vitamin D supplementation up-regulates IL-6 and IL-17A gene expression in multiple
6 sclerosis patients. *Int Immunopharmacol.* 2015;28(1):414-9.
- 7 15. Miroliaee AE, Salamzadeh J, Shokouhi S, Sahraei Z. The study of vitamin D
8 administration effect on CRP and Interleukin-6 as prognostic biomarkers of ventilator
9 associated pneumonia. *J Crit Care.* 2018;44:300-5.
- 10 16. Kang Q, Zhang X, Liu S, Huang F. Correlation between the vitamin D levels and
11 asthma attacks in children: Evaluation of the effects of combination therapy of atomization
12 inhalation of budesonide, albuterol and vitamin D supplementation on asthmatic patients.
13 *Exp Ther Med.* 2018;15(1):727-32.
- 14 17. Goncalves-Mendes N, Talvas J, Duale C, Guttmann A, Corbin V, Marceau G, et al.
15 Impact of Vitamin D Supplementation on Influenza Vaccine Response and Immune
16 Functions in Deficient Elderly Persons: A Randomized Placebo-Controlled Trial. *Front*
17 *Immunol.* 2019;10:65.
- 18 18. Bueloni-Dias FN, Orsatti CL, Cangussu LM, Poloni PF, Spadoto-Dias D, Nahas-
19 Neto J, et al. Isolated vitamin D supplementation improves the immune-inflammatory
20 biomarkers in younger postmenopausal women: a randomized, double-blind, placebo-
21 controlled trial. *Menopause.* 2018;25(8):897-903.
- 22 19. Ramos-Martinez E, Lopez-Vancell MR, Fernandez de Cordova-Aguirre JC, Rojas-
23 Serrano J, Chavarria A, Velasco-Medina A, et al. Reduction of respiratory infections in

1 asthma patients supplemented with vitamin D is related to increased serum IL-10 and
2 IFNgamma levels and cathelicidin expression. *Cytokine*. 2018;108:239-46.

3 20. Barker T, Rogers VE, Levy M, Templeton J, Goldfine H, Schneider ED, et al.
4 Supplemental vitamin D increases serum cytokines in those with initially low 25-
5 hydroxyvitamin D: a randomized, double blind, placebo-controlled study. *Cytokine*.
6 2015;71(2):132-8.

7 21. Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R.
8 Vitamin D supplementation improves cytokine profiles in patients with congestive heart
9 failure: a double-blind, randomized, placebo-controlled trial. *Am J Clin Nutr*.
10 2006;83(4):754-9.

11
12
13
14
15
16
17
18
19
20
21
22

1

2

3 **FIGURE LEGENDS**

4 **Figure 1.** Longitudinal changes in blood 25(OH)D concentrations in Mongolian children.

5 Measurements were performed in vitamin D3 supplemented (n=25) and placebo (n=30)

6 groups. Circles and bars denote means and 95% confidence intervals, respectively.

7 Intraindividual changes within each group and inter-group differences were assessed by

8 paired t test and one-sample t test ($p < 0.05$), respectively. *p values < 0.001 , NS=not

9 significant.

10

11 **Figure 2.** Longitudinal changes in blood cytokine concentrations in Mongolian children.

12 Measurements were performed on serum samples from vitamin D3 supplemented (n=22)

13 and placebo (n=27) groups. Circles represent means of difference between Log-transformed

14 cytokine concentrations at the six-month follow-up visit and baseline. Bars are 95%

15 confidence intervals. Cytokine change is considered significant when its respective

16 confidence intervals are found entirely on the positive or negative sides of the x-axis and

17 are not spanning the “0” reference line. Stars denote cytokines (MIP-1 α , IL-8, IL-6)

18 exhibiting statistically significant changes ($p < 0.05$)- see **Supplementary Figure 1** for

19 participant-level data for these cytokines.




Fig. 1

Fig. 2

